



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

December 5, 2013

**CardioComm Solutions' HeartCheck™ Technologies to be used in
Canadian Parkinson's Research Study**

Second CIHR and industry sponsored study to use HeartCheck™ and SMART Monitoring Technologies

Toronto, Canada – CardioComm Solutions, Inc. (TSX-V:EKG) ("CardioComm Solutions" or the "Company"), a global medical provider of electrocardiogram ("ECG") acquisition and management software solutions, announced it shall be providing HeartCheck™ based ECG screening technologies to researchers from the Research Institute of the McGill University Health Centre (RI MUHC) and the Montreal General Hospital (Quebec, Canada). This research study, which will be funded by the Canadian Institutes of Health Research (CIHR) and the Webster Foundation, will evaluate the potential relationship between caffeine intake and improvements in motor symptoms of persons with Parkinson's disease ("PD").

The study, entitled "Caffeine for Motor Manifestations of Parkinson's Disease: An Open-Label Dose-Response Study," builds on prior research that examined the benefits of caffeine on motor impairment in people who have PD. A total of 250 PD patients with a disease duration of one (1) to six (6) years who have been on stable symptomatic therapy for six (6) months, have been free of dementia or severe depression and who have a baseline caffeine intake of 150mg per day will be screened for ECG abnormalities, and specifically supraventricular tachycardia, prior to entry into the study. "In this current research study, all patients will be screened by performing an electrocardiogram ("ECG") in our neurology clinic to ensure against the presence of supraventricular arrhythmias," stated Dr. Ronald Postuma, lead author of the study, a researcher in neurosciences at the RI MUHC, and Professor of Medicine in the Department of Neurology and Neurosurgery at McGill University.

"We are pleased to have been selected to participate in this research project, which is our second opportunity to work with researchers supported by CIHR funding. The opportunity to expand the use of our technologies beyond cardiology centred projects provides independent scientific validation of the utility of our technologies and software as ECG screening and monitoring solutions. Dr. Postuma and his team will be using our HeartCheck™ ECG monitors to collect 30 second ECG recordings which will then be transferred to our patent pending SMART Monitoring ECG service via GEMS Home 1.2. Last month we extended the capacity of GEMS Home 1.2 to support the prescription version of our HeartCheck™ devices. Once transferred to GEMS Home, ECG records will be coded using study subject IDs and then uploaded to our SMART Monitoring servers where the researchers will log in to review and interpret their patient's ECGs themselves. This ability to determine how the SMART Monitoring ECG service is configured, based on required work flow, speaks to the power and stability of our services," said Etienne Grima, Chief Executive Officer for CardioComm Solutions.

"CardioComm Solutions will continue in its efforts to expand use of its HeartCheck™ and SMART Monitoring technologies through research, pharmacy and consumer-based HeartCheck™ Partner Program distribution efforts in Canada and the USA. Recent interest has included monitoring of post cardiac ablation patients for recurrent atrial fibrillation, monitoring of arrhythmias in heart failure patients in long-term care facilities and continued public screening programs," said Mr. Simi Grosman, member of the Board of Directors of the Company.

About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions, Inc. is headquartered in Toronto, Canada, with offices in Victoria, B.C.

For Further Information On CardioComm Solutions Please Contact:

Etienne Grima, Chief Executive Officer
1-877-977-9425
egrima@cardiocomm.com
www.cardiocomm.com

Forward-looking statements

This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause



actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release